title: Intravesical Evans Bacille Calmette-Guérin in the treatment of carcinoma in situ.
abstract: We report our experience in the treatment of carcinoma in situ of the urinary bladder using Evans strain Bacille Calmette-Guérin (BCG). The mean period of follow-up was 30 months; 18 patients received intravesical therapy and 16 of these were evaluable. They received 8 weekly instillations of 60 mg Evans strain BCG in 50 ml of saline. No intradermal BCG was given. The response rate was 93.75% at 3 months; this declined to 57% at 2 years. The complications of therapy were frequent but mild. Seven patients failed to complete the course. These results were comparable to those obtained with other strains of Bacille Calmette-Guérin.
authors.affiliation: University Department of Surgery/Urology, Western General Hospital, Edinburgh.
authors.forename: J A
authors.initials: JA
authors.lastname: Cumming
authors.forename: T B
authors.initials: TB
authors.lastname: Hargreave
authors.forename: J N
authors.initials: JN
authors.lastname: Webb
authors.forename: M A
authors.initials: MA
authors.lastname: McIntyre
authors.forename: G D
authors.initials: GD
authors.lastname: Chisholm
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
chemical_list: D001500:BCG Vaccine